BiotechTube

NBI-98854 50 mg capsule

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
30
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Conditions

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Trial Timeline

Aug 1, 2013 โ†’ Dec 1, 2013

NCT ID
NCT01916993

About NBI-98854 50 mg capsule

NBI-98854 50 mg capsule is a phase 1 stage product being developed by Neurocrine Biosciences for Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01916993. Target conditions include Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01916993Phase 1Completed

Competing Products

20 competing products in Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

See all competitors
ProductCompanyStageHype Score
LPH-5 + PlaceboBiotrialPhase 1
25
DS-1971 + placeboDaiichi SankyoPhase 1
33
ASP7962 + PlaceboAstellas PharmaPhase 1
33
ASP2151 + Valacyclovir + PlaceboAstellas PharmaPhase 1
33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)AstraZenecaPhase 1
33
AZD7594 + Placebo to matchAstraZenecaPhase 1
33
Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tabletAstraZenecaPhase 1
33
AZD4721 Solution + AZD4721 Placebo + AZD4721 SuspensionAstraZenecaPhase 1
33
AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solutionAstraZenecaPhase 1
33
AZD3043AstraZenecaPhase 1
33
AZD8848 + Placebo to match AZD8848AstraZenecaPhase 1
33
AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + PrednisoloneAstraZenecaPhase 1
33
AZD7503 + PlaceboAstraZenecaPhase 1
33
Fluad + SalineNovartisApproved
85
TBM100NovartisApproved
85
VIB9600 + PlacebosAmgenPhase 1
32
DenosumabAmgenPhase 3
76
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and FluorouracilAkesoPhase 2
51
HTL0018318 + Placebo oral capsuleNxera PharmaPhase 1
32

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82